Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: The results of the KKESH international collaborative retina study group
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams and Wilkins
Abstract
PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option. Copyright © by Ophthalmic Communications Society, Inc.
Description
Keywords
Antiangiogenic therapy, Children, Choroidal neovascularization, Adolescent, Angiogenesis inhibitors, Antibodies, monoclonal, humanized, Child, Child, preschool, Female, Follow-up studies, Humans, Intervention studies, Intravitreal injections, Male, Retrospective studies, Tomography, optical coherence, Treatment outcome, Vascular endothelial growth factor a, Visual acuity, Bevacizumab, Immunoglobulin g, Ranibizumab, Angiogenesis inhibitor, Monoclonal antibody, Vasculotropin a, Vegfa protein, human, Article, Choroid disease, Choroidal osteoma, Clinical article, Cohort analysis, Disease severity, Drug safety, Fluorescence angiography, Follow up, Human, Immunoglobulin blood level, Intervention study, Macular degeneration, Macular thickness, Multicenter study, Ophthalmoscopy, Osteoma, Photodynamic therapy, Preschool child, Retina edema, Retina macula hemorrhage, Retrospective study, School child, Spectral domain optical coherence tomography, Subretinal neovascularization, Treatment duration, Uveitis, Visual impairment, Antagonists and inhibitors, Case report, Clinical trial, Intravitreal drug administration, Optical coherence tomography, Pathophysiology, Physiology